Morgan Stanley Procept Bio Robotics Corp Transaction History

Morgan Stanley

$1.39 Trillion
Q4 2024

A detailed history of Morgan Stanley transactions in Procept Bio Robotics Corp stock. As of the latest transaction made, Morgan Stanley holds 757,400 shares of PRCT stock, worth $46.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

757,400

Previous 650,773 16.38%

Holding current value

$46.1 Million

Previous $52.1 Million 16.98%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$67.27 - $99.45 $7.17 Million - $10.6 Million	106,627 Added 16.38%	757,400 $61 Million
Q3 2024 Nov 14, 2024	BUY	$56.31 - $84.99 $4.63 Million - $6.99 Million	82,268 Added 14.47%	650,773 $52.1 Million
Q2 2024 Oct 17, 2024	BUY	$45.73 - $69.19 $12 Million - $18.2 Million	262,338 Added 85.68%	568,505 $34.7 Million
Q2 2024 Aug 14, 2024	BUY	$45.73 - $69.19 $12 Million - $18.2 Million	262,338 Added 85.68%	568,505 $34.7 Million
Q1 2024 Oct 17, 2024	SELL	$40.38 - $50.75 $10.6 Million - $13.3 Million	-262,338 Reduced 46.15%	306,167 $15.1 Million
Q1 2024 Aug 16, 2024	BUY	$40.38 - $50.75 $3.91 Million - $4.91 Million	96,744 Added 46.2%	306,167 $15.1 Million
Q1 2024 May 15, 2024	BUY	$40.38 - $50.75 $3.91 Million - $4.91 Million	96,744 Added 46.2%	306,167 $15.1 Million
Q4 2023 Aug 16, 2024	SELL	$24.89 - $43.41 $8.94 Million - $15.6 Million	-359,082 Reduced 63.16%	209,423 $8.78 Million
Q4 2023 Feb 13, 2024	BUY	$24.89 - $43.41 $3 Million - $5.24 Million	120,634 Added 135.87%	209,423 $8.78 Million
Q3 2023 Nov 15, 2023	SELL	$30.02 - $38.81 $1.05 Million - $1.36 Million	-34,981 Reduced 28.26%	88,789 $2.91 Million
Q2 2023 Aug 14, 2023	SELL	$26.7 - $37.02 $388,725 - $538,974	-14,559 Reduced 10.52%	123,770 $4.38 Million
Q1 2023 May 15, 2023	SELL	$26.64 - $39.74 $174,971 - $261,012	-6,568 Reduced 4.53%	138,329 $3.93 Million
Q4 2022 Feb 14, 2023	BUY	$38.78 - $46.78 $2.39 Million - $2.88 Million	61,610 Added 73.97%	144,897 $6.02 Million
Q3 2022 Nov 14, 2022	BUY	$30.9 - $50.65 $817,644 - $1.34 Million	26,461 Added 46.56%	83,287 $3.45 Million
Q2 2022 Oct 27, 2022	SELL	$29.23 - $44.45 $197,390 - $300,170	-6,753 Reduced 10.62%	56,826 $1.86 Million
Q2 2022 Aug 15, 2022	SELL	$29.23 - $44.45 $197,390 - $300,170	-6,753 Reduced 10.62%	56,826 $1.86 Million
Q1 2022 Oct 27, 2022	BUY	$16.89 - $35.74 $114,058 - $241,352	6,753 Added 11.88%	63,579 $2.22 Million
Q1 2022 May 13, 2022	BUY	$16.89 - $35.74 $417,284 - $882,992	24,706 Added 63.56%	63,579 $2.22 Million
Q4 2021 Feb 14, 2022	BUY	$24.6 - $46.29 $951,355 - $1.79 Million	38,673 Added 19336.5%	38,873 $973,000
Q3 2021 Nov 15, 2021	BUY	$35.91 - $41.94 $7,181 - $8,388	200 New	200 $8,000

Others Institutions Holding PRCT

# of Institutions

294

Shares Held

40.1M

Call Options Held

196K

Put Options Held

141K

View Full List

About PROCEPT BioRobotics Corp

Ticker PRCT
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 44,592,300
Market Cap $2.72B
Description
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aqu...

More about PRCT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account